Vol.

No.

January 05, 2018Jan 05, 2018

Free

DOWNLOAD THE PDF

ASCO forms collaboration with two Big Data firms to grow CancerLinQ

Cover Story

Free

ASCO forms collaboration with two Big Data firms to grow CancerLinQ

By Paul Goldberg

The American Society of Clinical Oncology has reached a deal that will allow two companies—Tempus and Precision Health AI—to curate and license the data in CancerLinQ, the professional society's venture into Big Data.

Conversation with The Cancer Letter Free

Hudis: ASCO needed collaborators to help CancerLinQ deliver faster on its mission

By Paul Goldberg

Conversation with The Cancer Letter Free

Lefkofsky: CancerLinQ has value in ushering in an era of precision medicine

By Paul Goldberg

Free

Introducing the clinical section of The Cancer Letter

By Paul Goldberg

Free Obituary

Jimmie Holland, founder of psycho-oncology, dies at 89

By William Breitbart

Free Obituary

Gerald Hanks, pioneering radiation oncologist, dies at 83

By Eric Horwitz

Clinical Free Trials & Tribulations

Cabozantinib in first-line treatment of metastatic renal cell carcinoma

By Tian Zhang, Michael J. Morris, Darren R. Feldman, Toni K. Choueiri and Daniel J. George

In Brief

Howard “Skip” Burris elected ASCO president for 2019-2020

Hochster named associate director, clinical research, and chief of GI med/onc at Rutgers

Whitten named president of Taiho Oncology

Purdue Center for Cancer Research receives $10 million from Walther Cancer Foundation

METAvivor announces 2017 grant awards for metastatic cancer research

JAX starts canine cancer initiative to find predictors, treatments for humans, dog

Clinical Roundup

CAP publishes guideline to ensure accurate HPV testing in head and neck cancers

CAR-T therapy cancer study published in the New England Journal of Medicine

Cancer mortality in the U.S. continues decades-long drop

Drugs & Targets

FDA approves Perjeta in adjuvant breast cancer

FDA approves Cabometyx for previously untreated advanced renal cell carcinoma

FDA approves Pfizer's Bosulif (bosutinib) for newly-diagnosed Ph+ CML

FDA approves Xgeva for prevention of skeletal-related events in multiple myeloma

Kisqali receives breakthrough designation for HR+/HER2- breast cancer

FDA accepts sBLA, grants priority review for Adcetris

FDA grants breakthrough designation for Avelumab in combination with Inlyta in RCC

FDA grants orphan drug designation to Aptose Biosciences for CG'806 in AML

FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated NSCLC

FDA grants priority review for Apalutamide in non-metastatic castration-resistant prostate cancer

Janssen and Legend Biotech enter deal to develop CAR-T therapy

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 44 - November 22, 2024

ASCO forms collaboration with two Big Data firms to grow CancerLinQ

Hudis: ASCO needed collaborators to help CancerLinQ deliver faster on its mission

Lefkofsky: CancerLinQ has value in ushering in an era of precision medicine

Introducing the clinical section of The Cancer Letter

Jimmie Holland, founder of psycho-oncology, dies at 89

Gerald Hanks, pioneering radiation oncologist, dies at 83

Cabozantinib in first-line treatment of metastatic renal cell carcinoma

In Brief

Howard “Skip” Burris elected ASCO president for 2019-2020

Hochster named associate director, clinical research, and chief of GI med/onc at Rutgers

Whitten named president of Taiho Oncology

Purdue Center for Cancer Research receives $10 million from Walther Cancer Foundation

METAvivor announces 2017 grant awards for metastatic cancer research

JAX starts canine cancer initiative to find predictors, treatments for humans, dog

Clinical Roundup

CAP publishes guideline to ensure accurate HPV testing in head and neck cancers

CAR-T therapy cancer study published in the New England Journal of Medicine

Cancer mortality in the U.S. continues decades-long drop

Drugs & Targets

FDA approves Perjeta in adjuvant breast cancer

FDA approves Cabometyx for previously untreated advanced renal cell carcinoma

FDA approves Pfizer's Bosulif (bosutinib) for newly-diagnosed Ph+ CML

FDA approves Xgeva for prevention of skeletal-related events in multiple myeloma

Kisqali receives breakthrough designation for HR+/HER2- breast cancer

FDA accepts sBLA, grants priority review for Adcetris

FDA grants breakthrough designation for Avelumab in combination with Inlyta in RCC

FDA grants orphan drug designation to Aptose Biosciences for CG'806 in AML

FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated NSCLC

FDA grants priority review for Apalutamide in non-metastatic castration-resistant prostate cancer

Janssen and Legend Biotech enter deal to develop CAR-T therapy

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login